Inhibition of Tumor Growth against Chemoresistant Cholangiocarcinoma by a Proapoptotic Peptide Targeting Interleukin-4 Receptor

• DOI: 10.1021/acs.molpharmaceut.0c00529
• Publication Date: 2020-09-03T17:19:45Z
• Authors: Uttapol Permpoon; Fatima Khan; Sri Murugan Poonk...; Smriti Gurung; Gowri Rangaswamy ...; Min-Jong Kim; Sang-Hyun Kim; Peti Thuwajit; Byungheon Lee
• Keywords: 0301 basic medicine; Mice, Inbred BALB C; Carcinogenesis; Interleukin-4 Receptor alpha Subunit; Mice, Nude; Apoptosis; Xenograft Model Antitumor Assays; Tumor Burden; 3. Good health; Cholangiocarcinoma; Mice; 03 medical and health sciences; Drug Delivery Systems; Treatment Outcome; Bile Duct Neoplasms; Drug Resistance, Neoplasm; Cell Line, Tumor; Animals; Humans; Intercellular Signaling Peptides and Proteins; Fluorouracil

Cholangiocarcinoma (CCA) has a poor prognosis and high chemoresistance. Interleukin-4 receptor (IL-4R) is overexpressed in several cancer cells and plays a crucial role in tumor progression and drug resistance. IL4RPep-1, an IL-4R-binding peptide, has been identified by phage display and used for tumor targeting. In this study, we exploited IL4RPep-1 to guide the tumor-specific delivery of a proapoptotic peptide to chemoresistant CCA, thereby inhibiting tumor growth. Immunohistochemistry of human primary CCA tissues showed that IL-4R levels were upregulated in moderately to poorly differentiated types, and higher levels of IL-4R are correlated with lower survival rates in patients with CCA. IL4RPep-1 was observed to preferentially bind with high IL-4R-expressing KKU-213 human CCA cells, whereas it barely bound with low IL-4R-expressing KKU-055 cells. A hybrid of IL4RPep-1 and a proapoptotic peptide (KLAKLAK)2 (named as IL4RPep-1-KLA) induced cytotoxicity and apoptosis in KKU-213 cells and increased those levels induced by 5-fluorouracil (5-FU). IL4RPep-1-KLA was internalized in the cells and colocalized with mitochondria. Whole-body fluorescence imaging and immunohistochemical analysis of tumor tissues showed the homing of IL4RPep-1-KLA as well as IL4RPep-1 to KKU-213 tumor in mice. Systemic administration of IL4RPep-1-KLA efficiently inhibited KKU-213 tumor growth, whereas treatment with 5-FU alone did not significantly inhibit tumor growth in mice. No significant systemic side effects including liver toxicity and immunotoxicity were observed in mice during peptide treatments. These findings suggest that IL4RPep-1-KLA holds potential as a targeted therapeutic agent against chemoresistant CCA.